Pharmafile Logo
Pharmafocus logo
Advanced Search

Manufacturing and Production

Showing 15 posts of 5862 posts found.

davidmeek

Ipsen’s CEO to step down, names new chief executive

July 11, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Ipsen (Euronext: IPN) said its chief executive Marc de Garidel is stepping down and will be replaced by David Meek, …
Appointment
stocks1

Weekly Movers: Medivation, Bind Therapeutics, Insys…

July 11, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Medivation, XBiotech, juno therapeutics, markets, stocks

Medivation (Nasdaq: MDVN) stock rose after the company announced it has entered a confidentiality agreement with a number of parties …
Feature

Wickham Laboratories Announces New In Vitro Pyrogenicity Testing Method

July 6, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing

Wickham Laboratories is pleased to announce the introduction of a new in vitro test method, the Monocyte Activation Test, for …
News
Press release

Nice rejects BMS’ immunotherapy Opdivo for previously treated kidney cancer on pricing

July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Bristol-Myers Squibb, NICE, QALY, immunotherapy, opdivo, regulation

UK regulators have rejected Bristol-Myers Squibb’s (NYSE: BMY) immunotherapy Opdivo for previously treated kidney cancer on pricing and substantial uncertainty …
News

UCB scores Japanese approval for seizure therapy, Vimpat

July 5, 2016 Manufacturing and Production, Research and Development Daiichi Sankyo, Japan, UCB, japanese

UCB Biopharma (EURONEXT: UCB) and Daiichi Sankyo have announced that Vimpat (lacosamide) has been approved as an adjunctive therapy in …
News

Sanofi, Regeneron say cholesterol drug Praluent approved in Japan

July 5, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Japan, Regeneron, Sanofi, cardiovascular, cholestrol, praleunt

Sanofi (Euronext: SAN) and Regeneron Pharmaceuticals (Nasdaq: REGN) said the lawmakers in Japan have granted marketing and manufacturing authorization for …
News
stocks1

Weekly Movers: Regulus, Nymox, Akers…

July 4, 2016 Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Shares, drug trial, markets, stocks

Shares in Regulus Therapeutics (Nasdaq: RGLS) dropped after the company said it has received verbal notification from the US Food …
Feature

Roche says EMA accepts its marketing applications for Ocrevus to treat multiple sclerosis

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing EMA, Ocrevus, Roche, US FDA, drug development, drug trial, multiple sclerosis, priority review, regulation

Cancer drugmaker Roche (SIX: ROG) said the European Medicines Agency (EMA) has accepted the marketing authorisation application (MAA) for its …
News
novo_flag

Novo Nordisk says its insulin pump secures EMA marketing authorisation

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing EMA, Novo Nordisk, insulin pump, marketing, product launch

Diabetes drugmaker Novo Nordisk (NYSE: NYO) said it has secured European Medicines Agency (EMA) marketing approval for its insulin pump.  …
News

Bristol-Myers Squibb’s Opdivo gets US FDA breakthrough therapy designation for advanced bladder cancer

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Breakthrough Therapy Designation, Bristol-Myers Squibb, FDA, bladder cancer, opdivo, regulation

Bristol-Myers Squibb (NYSE:BMY) said the US Food and Drug Administration (FDA) has granted breakthrough therapy designation to its immunotherapy Opdivo for the …
News
msd

MSD gets CHMP positive opinion for keytruda to treat advanced lung cancer

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing CHMP, EMA, MSD, Merck & Co, keytruda, lung cancer

MSD (Merck & Co) said its anti-programmed death-1 (PD-1) therapy, Keytruda (pembrolizumab) to treat lung cancer has secured a positive …
News
novartis_outside_1

Novartis signs $150 million deal with Xencor to develop bispecific antibodies

June 28, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Cancer, Novartis, Xencor, bispecific antibodies, deal, drug development, drug trial

Swiss drugmaker Novartis (VTX: NOVN) said it has signed a $150 million upfront collaboration and licensing agreement with Xencor to …
News
takeda_world

Takeda to return molecules/ products for Japan to Amgen

June 27, 2016 Manufacturing and Production, Research and Development, Sales and Marketing Amgen, Cancer, Japan, Takeda Pharmaceutical, drug development, drug trial

Japanese firm Takeda Pharmaceutical (TSE: 4502) said it will return the rights to develop and market multiple molecules/ products from …
News
brexit

“Immediate challenges” for UK pharma post-Brexit, says ABPI

June 24, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing ABPI, brexit

The UK life sciences industry has expressed dismay at the result of the EU referendum, but has pledged to work …
News

Murdo Gordon gets Chief Commercial Officer role at Bristol-Myers Squibb

June 21, 2016 Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, chief commercial officer

Bristol-Myers Squibb (NYSE: BMY) has announced the appointment of Munro Gordon as executive vice president and chief commercial officer, effective …
Appointment
The Gateway to Local Adoption Series

Latest content

Five Facts about the menopause

March 6, 2026

Zello Appoints Kevin Bailey as Group Chief Medical Officer

March 6, 2026

BioDuro establishes joint manufacturing venture with Cenra

March 6, 2026

Symbiosis appoints Joanne Anderson as Chief Commercial Officer

March 6, 2026

Secarna Pharmaceuticals and Curie.Bio expand existing partnership

March 6, 2026